摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

pyridin-1-ium [(3S,8S,9S,10R,13R,14S,17R)-17-[(1R)-1,5-dimethylhexyl]-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-yl]sulfate | 2515-23-3

中文名称
——
中文别名
——
英文名称
pyridin-1-ium [(3S,8S,9S,10R,13R,14S,17R)-17-[(1R)-1,5-dimethylhexyl]-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-yl]sulfate
英文别名
[(3S,8S,9S,10R,13R,14S,17R)-10,13-dimethyl-17-[(2R)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-yl] hydrogen sulfate;pyridine
pyridin-1-ium [(3S,8S,9S,10R,13R,14S,17R)-17-[(1R)-1,5-dimethylhexyl]-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-yl]sulfate化学式
CAS
2515-23-3
化学式
C5H5N*C27H46O4S
mdl
——
分子量
545.827
InChiKey
MSSPRGORCCARRU-KPNWGBFJSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    7.37
  • 重原子数:
    38
  • 可旋转键数:
    6
  • 环数:
    5.0
  • sp3杂化的碳原子比例:
    0.78
  • 拓扑面积:
    89
  • 氢给体数:
    1
  • 氢受体数:
    4

反应信息

点击查看最新优质反应信息

文献信息

  • [EN] CRYSTALLINE AND LIQUID CRYSTALLINE 25-HYDROXY-CHOLEST-5-EN-3-SULFATE SODIUM AND METHODS FOR PREPARING SAME<br/>[FR] 25-HYDROXY-CHOLEST-5-EN-3-SULFATE SODIQUE CRISTALLIN ET CRISTALLIN LIQUIDE ET SES PROCÉDÉS DE PRÉPARATION
    申请人:DURECT CORP
    公开号:WO2021133976A1
    公开(公告)日:2021-07-01
    Crystalline and liquid crystalline forms of 25HC3S sodium are described herein. The disclosure includes Forms I, II, III, V, IX, XI, and XIII of 25HC3S sodium and combinations thereof. Pharmaceutical formulations of said forms, or combinations thereof, and methods of treating or preventing disease such as hypercholesterolemia, hypertriglyceridemia, and conditions related to fat accumulation and inflammation (e.g., non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), alcoholic hepatitis, acute kidney injury (AKI), psoriasis, and atherosclerosis) are further disclosed herein. Methods for preparing 25HC3S are also provided
    本文描述了25HC3S钠的结晶和液晶形式。公开包括25HC3S钠的I、II、III、V、IX、XI和XIII形式及其组合。还公开了所述形式或其组合的药物配方,以及治疗或预防高胆固醇血症、高甘油三酯血症以及与脂肪积累和炎症相关的疾病(例如非酒精性脂肪肝病(NAFLD)、非酒精性脂肪性肝炎(NASH)、酒精性肝炎、急性肾损伤(AKI)、牛皮癣和动脉粥样硬化)的方法也在此公开。还提供了制备25HC3S的方法。
  • [EN] 25-HYDROXY-CHOLEST-5-EN-3-SULFATE CHOLINE AND METHODS FOR PREPARING, AND USES OF, SAME<br/>[FR] 25-HYDROXY-CHOLEST-5-EN-3-SULFATE CHOLINE, LEURS PROCÉDÉS DE PRÉPARATION, ET LEURS UTILISATIONS
    申请人:DURECT CORP
    公开号:WO2022272103A1
    公开(公告)日:2022-12-29
    25HC3S choline and crystalline 25HC3S choline are described herein. Pharmaceutical formulations of 25HC3S choline such as with crystalline 25HC3S choline and methods of treating or preventing disease with same such as hypercholesterolemia, hypertriglyceridemia, and conditions related to fat accumulation and inflammation (e.g., non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), alcoholic hepatitis, acute kidney injury (AKI), psoriasis, and atherosclerosis) are further disclosed herein. Methods for preparing 25HC3S, including crystalline 25HC3S choline, are also provided.
    本文介绍了25HC3S胆碱和结晶25HC3S胆碱。本文还介绍了25HC3S胆碱的药物制剂,例如与结晶25HC3S胆碱一起治疗或预防高胆固醇血症、高甘油三酯血症以及与脂肪积累和炎症相关的疾病(例如非酒精性脂肪肝病(NAFLD)、非酒精性脂肪性肝炎(NASH)、酒精性肝炎、急性肾损伤(AKI)、牛皮癣和动脉粥样硬化)。本文还提供了制备25HC3S(包括结晶25HC3S胆碱)的方法。
  • Natelson; Sobel; Kramer, Journal of Biological Chemistry, 1934, vol. 105, p. 761,763
    作者:Natelson、Sobel、Kramer
    DOI:——
    日期:——
  • Mandel; Neuberg, Biochemische Zeitschrift, 1915, vol. 71, p. 181
    作者:Mandel、Neuberg
    DOI:——
    日期:——
  • Natelson; Gottfried, Journal of the American Chemical Society, 1939, vol. 61, p. 971,972
    作者:Natelson、Gottfried
    DOI:——
    日期:——
查看更多